Recombinant lnterleukin-2 and Interf eron Alpha Immunotherap&amp;gamma; following Autologous Bone Marrow Transplantation

Schechter, David Chas.; Nagler, Arnon; Ackerstein, Aliza; Nassar, Hanan R.; Admon, Dan; Naparstek, Elizabeth; Rein, Andrea

doi:10.1159/000174999

Cited by 9 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High dose of cyclophosphamide may cause malignant arrhythmias inducing sometimes fatal outcomes [36]. The most severe EKG alterations of interferon-α and interleukin-2 correspond to supra-ventricular and ventricular arrhythmias [37]. Effort EKG test may be useful to unmask coronary artery spasm induced by capecitabine, showing ST-segment elevation accompanied by angina [38].…”

Section: Ekg and Cardiotoxicity Of Ctmentioning

confidence: 99%

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Galderisi

Marra

Esposito

et al. 2007

Cardiovasc Ultrasound

View full text Add to dashboard Cite

Cancer therapy has shown terrific progress leading to important reduction of morbidity and mortality of several kinds of cancer. The therapeutic management of oncologic patients includes combinations of drugs, radiation therapy and surgery. Many of these therapies produce adverse cardiovascular complications which may negatively affect both the quality of life and the prognosis. For several years the most common noninvasive method of monitoring cardiotoxicity has been represented by radionuclide ventriculography while other tests as effort EKG and stress myocardial perfusion imaging may detect ischemic complications, and 24-hour Holter monitoring unmask suspected arrhythmias. Also biomarkers such as troponine I and T and B-type natriuretic peptide may be useful for early detection of cardiotoxicity. Today, the widely used non-invasive method of monitoring cardiotoxicity of cancer therapy is, however, represented by Doppler-echocardiography which allows to identify the main forms of cardiac complications of cancer therapy: left ventricular (systolic and diastolic) dysfunction, valve heart disease, pericarditis and pericardial effusion, carotid artery lesions. Advanced ultrasound tools, as Integrated Backscatter and Tissue Doppler, but also simple ultrasound detection of "lung comet" on the anterior and lateral chest can be helpful for early, subclinical diagnosis of cardiac involvement. Serial Doppler echocardiographic evaluation has to be encouraged in the oncologic patients, before, during and even late after therapy completion. This is crucial when using anthracyclines, which have early but, most importantly, late, cumulative cardiac toxicity. The echocardiographic monitoring appears even indispensable after radiation therapy, whose detrimental effects may appear several years after the end of irradiation.

show abstract

Section: Ekg and Cardiotoxicity Of Ctmentioning

confidence: 99%

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Galderisi

Marra

Esposito

et al. 2007

Cardiovasc Ultrasound

View full text Add to dashboard Cite

show abstract

Adverse Effects of Interferon Treatment

Aul¹,

Gattermann²,

Germing³

et al. 1997

Interferons

View full text Add to dashboard Cite

Role of interleukin-2 in human hematological malignancies

et al. 1995

View full text Add to dashboard Cite

Clinical studies with Interleukin-2 (IL-2) in human hematologic malignancies were initiated in the late 1980s. Based on clinical studies on various solid tumors, and laboratory research on hematopoietic cells, IL-2 was shown to be effective in 150 acute myeloid leukemia (AML) patients mainly for maintenance therapy in first complete remission, or with residual blast cells in the marrow. IL-2 has also been shown to be effective in remission induction in 10 patients with chronic myeloid leukemia (CML). The role of IL-2 in lymphoma patients remains to be established. IL-2 alone or in combination with Interferon-alpha, may intensify remission and prolong disease-free survival when given post autologous bone marrow transplantation (BMT) to patients with lymphoma and myeloid leukemia, and to a lesser degree, to patients with acute lymphatic leukemia (ALL). IL-2 in combination with HLA-matched or mismatched peripheral blood lymphocytes was also used post autologous BMT in preliminary studies. IL-2 was administered with or without peripheral blood lymphocytes, for prevention of relapse post T-cell-depleted allogeneic BMT in CML, ALL and AML, with encouraging results. The same strategy was shown to be effective in the reinduction of remission in patients with CML, who relapsed post BMT.

show abstract

Recombinant lnterleukin-2 and Interf eron Alpha Immunotherapγ following Autologous Bone Marrow Transplantation

Cited by 9 publications

References 5 publications

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Adverse Effects of Interferon Treatment

Role of interleukin-2 in human hematological malignancies

Contact Info

Product

Resources

About